Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes
In this article:
Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.